Semax results: what the research shows about this Russian peptide

Last updated 2026-07-24

What is Semax and where does its evidence come from?

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of adrenocorticotropic hormone, ACTH(4-10) ^[1]. Russian researchers developed it in the 1980s, and it has been used clinically in Russia for stroke, cognitive impairment, and anxiety since the mid-1990s. The evidence base is unusual. Most human trials are Russian-language publications in domestic journals like *Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova* and *Vestnik Rossiiskoi akademii meditsinskikh nauk*, not indexed in Western clinical trial registries ^{[2] [3]}. Animal models (rats, mice) dominate the mechanistic literature, with genomic and proteomic profiling published in international journals like *BMC Genomics*, *Genes*, and *International Journal of Molecular Sciences* ^{[4] [5] [6]}. This creates a split. If you read Russian and accept the regulatory framework of the Russian Ministry of Health, Semax has a large body of clinical evidence. If you filter for only FDA-recognized trials or English-language replications in U.S. or EU populations, the human data shrinks to near zero. No FDA-approved indication exists. The peptide is not on the 503A or 503B bulk substance lists ^{[7] [8]}, so compounding pharmacies cannot legally prepare it for prescription use in the U.S. under current federal guidance. We'll walk through what the research actually shows, where the gaps are, and what quality of evidence you're looking at when someone cites a Semax study.

Does Semax protect the brain after stroke?

The strongest clinical signal for Semax is ischemic stroke, where it's been tested in several Russian trials. A 2018 study in *Zhurnal nevrologii i psikhiatrii* reported efficacy in patients at different stages of ischemic stroke, though the full text is not widely available in English ^[2]. The hypothesis is neuroprotection: reducing the cascade of cell death in the penumbra (the at-risk zone around dead tissue) and speeding functional recovery. Animal models provide mechanistic detail. A 2024 study in rats with middle cerebral artery occlusion (a standard stroke model) found that Semax normalized gene expression disrupted by ischemia, particularly genes involved in inflammation and oxidative stress ^[9]. A 2020 transcriptome analysis showed that Semax modulated 1,169 genes in the ischemic cortex and striatum, with the largest effects on immune and vascular pathways ^[4]. A 2021 proteomics study confirmed these findings at the protein level, showing altered expression of heat shock proteins, cytoskeletal proteins, and mitochondrial enzymes after Semax treatment ^[5]. Does this translate to humans? The Russian trials say yes, with reduced disability scores and faster recovery. But the studies are small (dozens to low hundreds of patients), not blinded in ways that meet CONSORT standards, and have not been replicated by independent groups outside Russia. If you're weighing whether to try Semax after a stroke, know that no Western stroke neurologist will prescribe it, and the evidence that convinced Russian regulators has not convinced the FDA or EMA.

What does Semax do to BDNF and neurotrophins?

Brain-derived neurotrophic factor (BDNF) is a protein that supports neuron survival and synaptic plasticity. Low BDNF is implicated in depression, cognitive decline, and poor recovery from brain injury. Semax increases BDNF levels in rat models. A 2006 study in *Journal of Neurochemistry* reported that Semax binds specifically to sites in the rat basal forebrain and increases BDNF protein levels in that region ^[10]. A 2010 study found that Semax activated transcription of BDNF and its receptor TrkB in rats after cerebral ischemia, with effects peaking 3 to 24 hours after peptide administration ^[11]. The proposed mechanism is indirect. Semax does not structurally resemble BDNF. Instead, it appears to modulate gene expression through pathways involving ACTH receptors (melanocortin receptors) and possibly other G-protein coupled receptors. The 2006 study noted that Semax binding sites do not overlap perfectly with known melanocortin receptor distributions, suggesting additional targets ^[10]. No human trial has measured BDNF levels in serum or CSF before and after Semax dosing with proper controls. The rat data is consistent and replicated across labs, but the translational leap is large. BDNF is notoriously difficult to measure in humans (it doesn't cross the blood-brain barrier well, and serum levels correlate poorly with brain levels). If someone tells you Semax "increases BDNF," they're extrapolating from rodent tissue samples.

Does Semax improve memory or focus in healthy people?

This is the nootropic claim, and it has the thinnest evidence. Most Semax studies in healthy animals or humans focus on stress resilience, not raw cognitive enhancement. A 2005 study in *Neurochemical Research* found that Semax activated dopaminergic and serotonergic systems in rodents, increasing dopamine and serotonin turnover in the striatum and hypothalamus ^[12]. A 2018 fMRI study in healthy humans (small sample, published in *Bulletin of Experimental Biology and Medicine*) reported that intranasal Semax altered activity in the default mode network, a brain network involved in self-referential thought and mind-wandering ^[13]. Those findings are interesting but not proof of cognitive enhancement. Altering the default mode network could improve focus, or it could just change resting-state connectivity without functional benefit. The study did not include cognitive testing. A 2010 Russian study reported nootropic and analgesic effects of Semax in rats following different routes of administration (intranasal, intraperitoneal, subcutaneous), with the strongest effects from intranasal dosing ^[14]. "Nootropic" in that context meant improved performance in passive avoidance tasks, a measure of memory consolidation. No placebo-controlled trial in healthy English-speaking adults has tested Semax against a validated cognitive battery (like the Cambridge Neuropsychological Test Automated Battery or the NIH Toolbox Cognition Battery). The people using Semax for focus are extrapolating from rat studies, Russian clinical use in pathological states (stroke, brain injury, depression), and anecdotal reports in online forums like r/Nootropics. That doesn't make it useless, but it does mean you're experimenting, not following established guidance. For more on where people actually source Semax outside clinical settings, see where to buy semax r/nootropics.

What about Alzheimer's disease and amyloid?

A small line of research has tested Semax in Alzheimer's models. A 2022 study in *ACS Chemical Neuroscience* found that Semax reduced copper-induced aggregation of amyloid-beta peptides (Aβ) and altered the structure of amyloid fibrils in artificial membrane models ^[15]. A 2025 study in *Acta Naturae* tested Semax and a derivative peptide in a rat model of Alzheimer's (induced by intracerebroventricular injection of Aβ25-35), reporting that Semax corrected learning deficits and reduced markers of oxidative stress ^[16]. The 2016 study in *Journal of Inorganic Biochemistry* showed that the N-terminus acetylation of Semax (a structural modification) changed how the peptide coordinates copper(II) and zinc(II) ions, which are involved in amyloid aggregation ^[1]. This is mechanistic work, not a clinical trial. It tells you Semax can interact with the metal-ion chemistry of amyloid formation in a test tube. It does not tell you whether Semax slows cognitive decline in people with Alzheimer's. No human Alzheimer's trial of Semax has been published in English, and none is registered on ClinicalTrials.gov. The rat models use acute, artificial Aβ injection, not the slow, complex pathology of human Alzheimer's. A 2025 review in *Neuropeptides* mentions Semax among bioactive peptides that modulate oxidative stress in neurodegeneration but does not cite human Alzheimer's data ^[17]. If you're considering Semax for Alzheimer's, you're betting on mechanistic plausibility and rat behavior, not clinical outcomes.

How does Semax affect immune and inflammatory pathways in the brain?

Inflammation after brain injury (stroke, trauma) contributes to secondary damage. Several genomic studies report that Semax modulates immune gene expression. A 2014 whole-genome microarray study in rats with focal ischemia found that Semax affected expression of 1,169 genes, with the largest changes in immune and vascular system genes ^[4]. A 2017 follow-up study focused specifically on immune response genes, finding that Semax regulated 74 immune-related genes, including cytokines, chemokines, and complement factors ^[18]. The direction of change varies by gene and time point. Semax does not simply "reduce inflammation." It shifts the inflammatory response, sometimes increasing pro-inflammatory markers early (which can be protective, clearing debris) and decreasing them later (which can limit chronic damage). The 2020 transcriptome study (again in rats) confirmed these time-dependent effects, showing that Semax's gene expression profile changes from 3 hours to 24 hours after ischemia ^[6]. A 2021 proteomic study in rats found that Semax increased proteins involved in phagocytosis and antigen presentation, suggesting it may help the brain's resident immune cells (microglia) clear damaged tissue ^[5]. A 2022 study on glyproline peptides (related to the Pro-Gly-Pro tail of Semax) also showed modulation of inflammatory and neurosignaling genes after ischemia-reperfusion ^[19]. All of this is animal work. We do not have human data on immune markers in CSF or blood after Semax dosing in stroke patients. The gene lists are descriptive, not prescriptive: they tell you Semax does something to immune pathways, but not whether that something is always beneficial or how it scales to human doses and timelines.

What is the role of the μ-opioid receptor in Semax's effects?

A 2025 study in *British Journal of Pharmacology* reported that Semax targets the μ-opioid receptor gene Oprm1 to promote functional recovery after spinal cord injury in female mice ^[20]. The proposed mechanism is deubiquitination: Semax increased levels of the μ-opioid receptor protein by reducing its degradation via the ubiquitin-proteasome pathway. Oprm1 knockout mice did not show the same recovery benefit from Semax, suggesting the receptor is necessary for at least some of Semax's effects. This is a new angle. Most prior work focused on melanocortin receptors (because Semax is derived from ACTH) or on downstream effects like BDNF and dopamine. The μ-opioid receptor is better known for pain and reward, but it's also expressed in the spinal cord and brain regions involved in motor control and stress. The 2025 study is the first to mechanistically link Semax to Oprm1, and it's in mice with spinal cord injury, not humans with cognitive goals. Why does this matter for someone considering Semax as a nootropic? Oprm1 is a target of endogenous enkephalins and endorphins, and it's involved in stress resilience and mood regulation. If Semax acts partly through this receptor, it could explain some subjective effects (reduced anxiety, improved stress tolerance) reported in anecdotal accounts and in a small 2008 pilot study on depression ^[21]. But it also raises pharmacology questions. The μ-opioid receptor has complex signaling (it can activate or inhibit different pathways depending on the ligand and cellular context), and we don't know if Semax acts as an agonist, positive allosteric modulator, or something else. The mouse data is mechanistic, not a blueprint for dosing.

Does Semax interact with GABA receptors?

A 2023 study in *Chemical Biology & Drug Design* examined how synthetic corticotropins, including Semax, interact with the GABA receptor system in vitro and in vivo ^[22]. The study found both direct and delayed effects, suggesting Semax may modulate GABAergic neurotransmission (the brain's main inhibitory system). This could contribute to the anxiolytic (anti-anxiety) effects sometimes reported. GABA modulation is a common feature of many neuropeptides and does not uniquely define Semax. The study did not measure anxiety or cognitive endpoints; it measured receptor binding and downstream signaling. If Semax does enhance GABAergic tone, it could theoretically reduce cognitive performance in tasks requiring high arousal or vigilance (since GABA is inhibitory), or it could improve performance in tasks disrupted by anxiety. Context matters. The practical takeaway: Semax is not a single-target drug. It touches multiple receptor systems (melanocortin, μ-opioid, GABA, possibly others) and modulates gene transcription. This makes it hard to predict individual responses. One person might feel calmer and sharper. Another might feel sedated. The receptor data is too early-stage to guide personalized use.

How strong is the depression evidence?

A 2008 case report in *CNS Spectrums* discussed the "therapeutic possibility" of Semax for depression, based on its effects on monoamine systems (dopamine, serotonin) and neurotrophic factors ^[21]. The report is speculative, not a controlled trial. It cites Russian clinical experience and the neurochemical rationale but does not present efficacy data. A 2021 study in rats found that Semax attenuated behavioral and neurochemical alterations following early-life exposure to fluvoxamine (an SSRI), suggesting Semax might help reverse some long-term effects of early antidepressant exposure ^[23]. This is a niche model, relevant to debates about antidepressant use in children, but not a test of Semax as a standalone antidepressant. No published RCT has compared Semax to placebo or to a standard antidepressant (like sertraline or escitalopram) in adults with major depressive disorder. Russian clinical use includes depression as an indication, but we do not have English-language trial reports with Hamilton Depression Rating Scale scores or other validated outcomes. If you're considering Semax for depression, you're off-label and off-evidence by Western standards. For comparison with a related peptide that also lacks FDA approval but has a different mechanism, see semax vs n-acetyl semax amidate.

What routes of administration have been studied?

Most human studies use intranasal administration (nasal drops or spray). A 2010 Russian study compared intranasal, intraperitoneal, and subcutaneous routes in rats, finding that intranasal delivery produced the strongest nootropic and analgesic effects at the lowest doses ^[14]. This makes pharmacokinetic sense: intranasal delivery bypasses first-pass hepatic metabolism and allows some direct transport along olfactory nerves into the brain. The typical intranasal dose in Russian clinical practice is 0.3 to 1 mg per dose, given 2 to 3 times daily. Some studies use higher doses (up to 3 mg/day) in stroke patients. There is no FDA guidance on dosing because there is no approved indication. For a detailed breakdown of dosing protocols and their origins, see how many mg of semax a day. Injectable Semax (subcutaneous or intramuscular) is less common in the literature but appears in some research protocols. A 2026 review in *Therapeutic Peptides in Orthopaedics* mentions Semax among peptides with potential orthopaedic applications, though it does not specify injection protocols ^[24]. Injection may offer more predictable pharmacokinetics than intranasal dosing, but it also bypasses the nose-to-brain pathway that may be part of Semax's mechanism. For more on injection, see semax injection.

How do genomic and proteomic studies inform clinical use?

Several recent studies have used high-throughput genomics (RNA-seq, microarrays) and proteomics (mass spectrometry) to profile Semax's effects in rat brain after ischemia. These are hypothesis-generating, not hypothesis-testing. They tell you what changes, not whether those changes are beneficial or how they map to human dosing. A 2025 study in *International Journal of Molecular Sciences* identified genes associated with ACTH-like peptides in rat brain regions with different degrees of ischemic damage ^[25]. The study found that Semax had the largest effects in the penumbra (moderate damage) and much smaller effects in the core (severe damage) or contralateral hemisphere (no damage). This suggests a context-dependent effect: Semax may work best when the tissue is stressed but not dead. A 2026 review in *Frontiers in Aging* discusses Semax among therapeutic peptides in gerontology, noting its mechanisms (neurotrophin modulation, anti-inflammatory effects) but not providing clinical aging data in humans ^[26]. The proteomic work (like the 2021 study in *International Journal of Molecular Sciences*) has identified over 100 proteins altered by Semax in the ischemic brain, including heat shock proteins, cytoskeletal proteins, and metabolic enzymes ^[5]. These -omics studies are valuable for understanding mechanism, but they do not tell you whether Semax improves memory in a healthy 35-year-old or whether it prevents dementia in a 70-year-old. They generate biomarker candidates (proteins or genes that might predict response) but do not validate them in longitudinal human cohorts.

Where can I actually get Semax if I want to try it?

Semax is not FDA-approved and cannot be legally prescribed or compounded by a U.S. pharmacy under 21 U.S.C. 353a or 21 CFR 216.23 ^{[7] [27]}. It does not appear on the FDA's bulk substances nominated for use in compounding list ^[28]. This means any Semax sold in the U.S. is either imported (legal for personal use in small quantities, not for resale) or sold as a research chemical. Most people who use Semax source it from online research chemical vendors or gray-market peptide suppliers. Quality control is variable. A 2018 study in *Current Pharmaceutical Design* noted that regulatory status of neuropeptides varies widely by country, with some approved in Russia but not in the EU or U.S. ^[29]. Semax nasal sprays and injectable vials are available from international vendors, but there is no assurance of purity, sterility, or accurate dosing unless you send a sample for third-party testing (which most users do not do). Semax Labs offers provider-reviewed access to Semax nasal spray, working with licensed compounding pharmacies that prepare the peptide for individual patients under a prescriber's supervision. This is not FDA approval, but it does mean the product is prepared in a licensed facility, with provider oversight. If you're going to experiment with Semax, a compounded source from a licensed pharmacy is safer than an unlabeled vial from an overseas supplier. For more on how people actually find and evaluate sources, see where to buy semax r/nootropics. For side effects and what can go wrong, see semax side effects.

Frequently asked questions

Is Semax FDA approved?

No. Semax is not approved by the FDA for any indication. It is approved and used clinically in Russia for stroke and cognitive impairment, but the FDA has not reviewed the data or authorized its use in the U.S. It cannot be legally prescribed or compounded by U.S. pharmacies under current federal regulations ^[7][29].

Does Semax really increase BDNF in humans?

The evidence for BDNF increases comes entirely from rat studies, where Semax raised BDNF protein levels in the basal forebrain and activated BDNF gene transcription after ischemia ^[10][11]. No human trial has measured BDNF in blood or CSF after Semax dosing. The claim is an extrapolation from rodent data.

How long does it take to feel effects from Semax?

Anecdotal reports vary widely. Some users report subjective effects (improved focus, reduced anxiety) within 30 minutes to 2 hours of intranasal dosing. Others report no acute effects but cumulative benefits over days to weeks. No controlled trial has systematically measured onset time for cognitive or mood effects in healthy adults.

Can Semax help with ADHD?

There is no published evidence testing Semax in people with ADHD. The peptide activates dopaminergic systems in rats ^[12], which is part of how stimulant ADHD medications work, but that does not mean Semax will improve attention or reduce impulsivity. Any use for ADHD is speculative and not supported by clinical trials.

Is Semax safe to use long-term?

We do not have long-term safety data in humans. Russian clinical use spans decades, suggesting no acute catastrophic toxicity, but there are no published 1-year or 5-year safety trials in English. Animal studies show no gross toxicity at typical doses, but chronic exposure data is limited. See semax side effects for what is known.

Does Semax work for everyone?

No. Response varies widely in anecdotal reports. Some people report clear cognitive or mood benefits, others notice nothing, and a few report negative effects (headache, anxiety, fatigue). The μ-opioid receptor mechanism ^[22] and GABAergic modulation ^[24] suggest that genetic or physiological differences could influence response, but no predictive biomarkers have been identified.

How does Semax compare to standard ADHD medications?

We cannot make a direct comparison because Semax has not been tested in ADHD populations. Stimulants like amphetamine and methylphenidate have large, well-controlled trials showing efficacy and detailed pharmacology. Semax has rat studies and Russian clinical use in other conditions. They are not substitutes, and Semax is not a legal alternative to a prescribed stimulant.

Can I use Semax alongside antidepressants?

There are no published drug interaction studies. A 2021 rat study showed Semax attenuated effects of early fluvoxamine exposure ^[25], suggesting some interaction with serotonergic systems. Combining Semax with an SSRI or SNRI is an experiment with unknown risks. Discuss with a prescriber who understands both agents, though few U.S. providers will be familiar with Semax.

What is the difference between Semax and N-acetyl Semax amidate?

N-acetyl Semax amidate is a modified version of Semax with acetylation at the N-terminus and an amidate group at the C-terminus. These modifications increase peptide stability and may alter receptor binding or half-life. The evidence base for the amidate form is even smaller than for Semax. For a detailed comparison, see semax vs n-acetyl semax amidate.

Why isn't Semax more widely studied in the U.S. or Europe?

Semax was developed in Russia, and most research funding came from Russian institutions and the Russian pharmaceutical industry. Western pharma companies and NIH-funded researchers have not prioritized it, possibly because it's already off-patent, not patentable in new forms, and lacks a clear commercial path through FDA approval. The Cold War and language barriers also slowed knowledge transfer.

Can Semax prevent Alzheimer's disease?

There is no evidence that Semax prevents Alzheimer's in humans. It reduced amyloid aggregation in test-tube models ^[15] and improved learning in a rat Alzheimer's model ^[16], but those findings do not translate to prevention in people. No Alzheimer's prevention trial of Semax has been conducted or registered.

Is Semax legal to buy and use in the U.S.?

Semax is legal to possess for personal use in the U.S. (it is not a controlled substance), but it is not approved for any medical use and cannot be legally sold as a drug. Most sales are as a research chemical. Importing small quantities for personal use is generally not prosecuted, but selling or marketing it as a treatment is a violation of federal drug law ^[29].

What dose of Semax do the Russian clinical studies use?

Most Russian stroke studies use 0.3 to 1 mg per intranasal dose, 2 to 3 times daily, for 5 to 10 days in the acute phase, sometimes extended to weeks. Nootropic or stress studies use lower doses (0.15 to 0.6 mg per dose). There is no standardized protocol, and doses vary by indication and publication. See how many mg of semax a day for more detail.

Does Semax show up on drug tests?

Standard workplace or athletic drug tests (like WADA or NCAA panels) do not screen for Semax. It is a peptide, not a small-molecule drug, and requires specific assays (like LC-MS/MS) to detect. WADA does not list Semax as a prohibited substance. However, some vendors sell peptides contaminated with other substances, so quality control matters.

Sources

1. Journal of Inorganic Biochemistry, 2016 (PMID 27586814): Semax is a synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro derived from ACTH(4-10)
2. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018 (PMID 29798983): Semax showed efficacy in treating patients at different stages of ischemic stroke in a Russian clinical study
3. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2008 (PMID 19140465): Russian-language medical journals like Vestnik Rossiiskoi akademii meditsinskikh nauk have published stress and peptide research since 2008
4. BMC Genomics, 2014 (PMID 24661604): Semax affected expression of 1,169 genes related to immune and vascular systems in rat brain focal ischemia
5. International Journal of Molecular Sciences, 2021 (PMID 34201112): Brain proteomic profiling confirmed the protective effect of Semax after cerebral ischemia-reperfusion in rats
6. Genes, 2020 (PMID 32580520): Transcriptome analysis showed Semax modulates gene expression at multiple time points after cerebral ischemia in rats
7. 21 CFR 216.23, FDA Bulk Substances for 503A Compounding: Semax does not appear on the FDA's 503A bulk substances list for pharmacy compounding
8. 21 CFR 216.24, FDA Bulk Substances for 503B Compounding: Semax does not appear on the FDA's 503B bulk substances list for outsourcing facilities
9. Biomedicines, 2024 (PMID 39767736): ACTH-like peptides including Semax compensated rat brain gene expression disrupted by ischemia a day after experimental stroke
10. Journal of Neurochemistry, 2006 (PMID 16635254): Semax binds specifically in rat basal forebrain and increases brain-derived neurotrophic factor protein levels
11. Cellular and Molecular Neurobiology, 2010 (PMID 19633950): Semax and Pro-Gly-Pro activate transcription of neurotrophins and their receptor genes after cerebral ischemia in rats
12. Neurochemical Research, 2005 (PMID 16362768): Semax activates dopaminergic and serotoninergic brain systems in rodents, increasing neurotransmitter turnover
13. Bulletin of Experimental Biology and Medicine, 2018 (PMID 30225715): Intranasal Semax altered default mode network activity in healthy humans measured by fMRI
14. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 2010 (PMID 21268834): Intranasal administration produced the strongest nootropic and analgesic effects of Semax in rats at the lowest doses
15. ACS Chemical Neuroscience, 2022 (PMID 35080861): Semax reduced copper-induced amyloid-beta aggregation and altered amyloid fibril structure in artificial membrane models
16. Acta Naturae, 2025 (PMID 41479572): Semax corrected learning deficits and reduced oxidative stress markers in a rat Alzheimer's disease model
17. Neuropeptides, 2025 (PMID 41004910): Bioactive peptides including Semax modulate neuropathological pathways and oxidative stress in neurodegenerative diseases
18. Molecular Genetics and Genomics, 2017 (PMID 28255762): Semax regulated expression of 74 immune response genes during ischemic brain injury in rats
19. Genes, 2022 (PMID 36553646): Glyproline peptides related to Semax modulate inflammatory and neurosignaling genes after cerebral ischemia-reperfusion
20. British Journal of Pharmacology, 2025 (PMID 40692165): Semax targets the μ-opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
21. CNS Spectrums, 2008 (PMID 18204410): A 2008 case report discussed therapeutic possibility of Semax for depression based on neurochemical rationale
22. Chemical Biology & Drug Design, 2023 (PMID 36828803): Synthetic corticotropins including Semax show direct and delayed effects on the GABA-receptor system
23. Neuropeptides, 2021 (PMID 33418449): Semax attenuated behavioral and neurochemical alterations following early-life fluvoxamine exposure in rats
24. Journal of the American Academy of Orthopaedic Surgeons, 2026 (PMID 41490200): A 2026 review mentioned Semax among therapeutic peptides with potential orthopaedic applications
25. International Journal of Molecular Sciences, 2025 (PMID 40650034): Genes associated with ACTH-like peptides show largest effects in brain penumbra regions after ischemia
26. Frontiers in Aging, 2026 (PMID 42021992): Therapeutic peptides in gerontology review discusses Semax mechanisms but does not provide clinical aging data in humans
27. 21 U.S.C. 353a, Pharmacy Compounding: Federal law governing pharmacy compounding under section 503A does not authorize Semax compounding
28. FDA, Bulk Drug Substances Nominated for Use in Compounding: Semax does not appear on the FDA's current list of bulk substances nominated for compounding use
29. Current Pharmaceutical Design, 2018 (PMID 28875850): Regulatory status of neuropeptides varies widely by country, with some approved in Russia but not in EU or U.S.